Semprus BioSciences is developing next-generation medical devices with anti-fouling modifications that are designed to provide the benefits of reducing complications such as thrombosis and microbial adhesion over long durations. Our core Semprus Sustain™ Technology* is a long-lasting, covalently bonded, non-leaching polymer that is designed to reduce the attachment of platelets and blood proteins at the device surface. It has been shown to reduce thrombus accumulation in in vitro testing after multi-month exposure to blood and in in vivo animal testing. The technology characteristics also mimic the chemical properties of endothelial cell membrane, potentially reducing the foreign body response to an implanted device.
Beyond products modified with Semprus Sustain™ Technology, we are also developing new products with the potential to reduce microbial adhesion, deliver drugs, bind with agents in the bloodstream, or provide improved accuracy for diagnostics.
The adaptability of these biomaterials to diverse substrates - such as polyurethane, silicone, and titanium - creates broad opportunities for enabling next-generation products with improved clinical benefits across the medical device spectrum.
*Not available for clinical use in the USA.